Investigation of immune and CNS-mediated effects of fingolimod in the focal delayed-type hypersensitivity multiple sclerosis model

Neuropharmacology

Volumn 79, Issue , 2014, Pages 534-541

  Anthony, Daniel C ^a   Sibson, Nicola R ^b   Losey, Patrick ^a   Meier, Daniela Piani ^c   Leppert, David ^d,e  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Blood brain barrier; Central nervous system; Delayed type hypersensitivity model; Fingolimod; Lesion; Multiple sclerosis

Indexed keywords

FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TISSUE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DEMYELINATION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LEUKOCYTE; LYMPHOCYTE; MACROPHAGE; MALE; MICROGLIA; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN; CAPILLARY PERMEABILITY; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; LEWIS RAT; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CAPILLARY PERMEABILITY; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTES; MACROPHAGES; MALE; MICROGLIA; MULTIPLE SCLEROSIS; PROPYLENE GLYCOLS; RATS; RATS, INBRED LEW; SPHINGOSINE;

EID: 84893169447     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2013.12.022     Document Type: Article

References (42)

1. Animals (Scientific Procedures) Act 1986. http://www.legislation.gov.uk/ ukpga/1986/14/contents. (accessed 12.03.13.).
2. O. Aktas, P. Kury, B. Kieseier, and H.P. Hartung Fingolimod is a potential novel therapy for multiple sclerosis Nat. Rev. Neurol. 6 2010 373 382
3. M.L. Allende, G. Tuymetova, B.G. Lee, E. Bonifacino, Y.P. Wu, and R.L. Proia S1P1 receptor directs the release of immature B cells from bone marrow into blood J. Exp. Med. 207 2010 1113 1124
4. D.C. Anthony, K.M. Miller, S. Fearn, M.J. Townsend, G. Opdenakker, G.M. Wells, J.M. Clements, S. Chandler, A.J. Gearing, and V.H. Perry Matrix metalloproteinase expression in an experimentally-induced DTH model of multiple sclerosis in the rat CNS J. Neuroimmunol. 87 1998 62 72 (Pubitemid 28319845)
5. D. Baker, and D.J. Jackson Models of multiple sclerosis ACNR 6 2007 10 12
6. B. Balatoni, M.K. Storch, E.M. Swoboda, V. Schonborn, A. Koziel, G.N. Lambrou, P.C. Hiestand, R. Weissert, and C.A. Foster FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis Brain. Res. Bull. 74 2007 307 316 (Pubitemid 47368881)
7. J. Bennett, J. Basivireddy, A. Kollar, K.E. Biron, P. Reickmann, W.A. Jefferies, and S. McQuaid Blood-brain barrier disruption and enhanced vascular permeability in the multiple sclerosis model EAE J. Neuroimmunol. 229 2010 180 191
8. V. Brinkmann, A. Billich, T. Baumruker, P. Heining, R. Schmouder, G. Francis, S. Aradhye, and P. Burtin Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis Nat. Rev. Drug. Discov. 9 2010 883 897
9. K.A. Broom, D.C. Anthony, A.M. Blamire, S. Waters, P. Styles, V.H. Perry, and N.R. Sibson MRI reveals that early changes in cerebral blood volume precede blood-brain barrier breakdown and overt pathology in MS-like lesions in rat brain J. Cereb. Blood Flow. Metab. 25 2005 204 216 (Pubitemid 40171202)
10. J.W. Choi, S.E. Gardell, D.R. Herr, R. Rivera, C.W. Lee, K. Noguchi, S.T. Teo, Y.C. Yung, M. Lu, G. Kennedy, and J. Chun FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation Proc. Natl. Acad. Sci. U. S. A. 108 2011 751 756
11. J. Chun, and V. Brinkmann A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya) Discov. Med. 12 2011 213 228
12. J.A. Cohen, F. Barkhof, G. Comi, H.P. Hartung, B.O. Khatri, X. Montalban, J. Pelletier, R. Capra, P. Gallo, G. Izquierdo, K. Tiel-Wilck, A. de Vera, J. Jin, T. Stites, S. Wu, S. Aradhye, and L. Kappos Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis N. Engl. J. Med. 362 2010 402 415
13. J.A. Cohen, and J. Chun Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis Ann. Neurol. 69 2011 759 777
14. A. Compston, and A. Coles Multiple sclerosis Lancet 372 2008 1502 1517
15. A. Denic, A.J. Johnson, A.J. Bieber, A.E. Warrington, M. Rodriguez, and I. Pirko The relevance of animal models in multiple sclerosis research Pathophysiology 18 2011 21 29
16. B. Ferguson, M.K. Matyszak, M.M. Esiri, and V.H. Perry Axonal damage in acute multiple sclerosis lesions Brain 120 Pt 3 1997 393 399 (Pubitemid 27153632)
17. C.A. Foster, L.M. Howard, A. Schweitzer, E. Persohn, P.C. Hiestand, B. Balatoni, R. Reuschel, C. Beerli, M. Schwartz, and A. Billich Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis J. Pharmacol. Exp. Ther. 323 2007 469 475
18. C.A. Foster, D. Mechtcheriakova, M.K. Storch, B. Balatoni, L.M. Howard, F. Bornancin, A. Wlachos, J. Sobanov, A. Kinnunen, and T. Baumruker FTY720 Rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of Central nervous system genes and reversal of blood-brain-barrier damage Brain. Pathol. 19 2008 254 266
19. R. Furlan, C. Cuomo, and G. Martino Animal models of multiple sclerosis Methods. Mol. Biol. 549 2009 157 173
20. L. Kappos, E.W. Radue, P. O'Connor, C. Polman, R. Hohlfeld, P. Calabresi, K. Selmaj, C. Agoropoulou, M. Leyk, L. Zhang-Auberson, and P. Burtin A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis N. Engl. J. Med. 362 2010 387 401
21. H.J. Kim, V.E. Miron, D. Dukala, R.L. Proia, S.K. Ludwin, M. Traka, J.P. Antel, and B. Soliven Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model Faseb. J. 25 2011 1509 1518
22. M.C. Kowarik, H.L. Pellkofer, S. Cepok, T. Korn, T. Kumpfel, D. Buck, R. Hohlfeld, A. Berthele, and B. Hemmer Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS Neurology 76 2011 1214 1221
23. A. Kulakowska, M. Zendzian-Piotrowska, M. Baranowski, T. Kononczuk, W. Drozdowski, J. Gorski, and R. Bucki Intrathecal increase of sphingosine 1-phosphate at early stage multiple sclerosis Neurosci. Lett. 477 2010 149 152
24. C. Mainero, T. Benner, A. Radding, A. van der Kouwe, R. Jensen, B.R. Rosen, and R.P. Kinkel In vivo imaging of cortical pathology in multiple sclerosis using ultra-high field MRI Neurology 73 2009 941 948
25. M.K. Matyszak, and V.H. Perry Demyelination in the central nervous system following a delayed-type hypersensitivity response to bacillus Calmette-Guerin Neuroscience 64 1995 967 977
26. M.K. Matyszak, M.J. Townsend, and V.H. Perry Ultrastructural studies of an immune-mediated inflammatory response in the CNS parenchyma directed against a non-CNS antigen Neuroscience 78 1997 549 560 (Pubitemid 27170344)
27. M. Mehling, V. Brinkmann, J. Antel, A. Bar-Or, N. Goebels, C. Vedrine, C. Kristofic, J. Kuhle, R.L. Lindberg, and L. Kappos FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis Neurology 71 2008 1261 1267
28. M. Mehling, T.A. Johnson, J. Antel, L. Kappos, and A. Bar-Or Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis Neurology 76 2011 S20 S27
29. V.E. Miron, S.K. Ludwin, P.J. Darlington, A.A. Jarjour, B. Soliven, T.E. Kennedy, and J.P. Antel Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices Am. J. Pathol. 176 2010 2682 2694
30. E. Mix, H. Meyer-Rienecker, H.P. Hartung, and U.K. Zettl Animal models of multiple sclerosis-potentials and limitations Prog. Neurobiol. 92 2010 386 404
31. T.A. Newman, S.T. Woolley, P.M. Hughes, N.R. Sibson, D.C. Anthony, and V.H. Perry T-cell- and macrophage-mediated axon damage in the absence of a CNS-specific immune response: involvement of metalloproteinases Brain 124 2001 2203 2214 (Pubitemid 33055365)
32. V.H. Perry, and R. Linden Evidence for dendritic competition in the developing retina Nature 297 1982 683 685 (Pubitemid 12096190)
33. I. Pirko, C.F. Lucchinetti, S. Sriram, and R. Bakshi Gray matter involvement in multiple sclerosis Neurology 68 2007 634 642 (Pubitemid 46667808)
34. A.P. Robinson, T.M. White, and D.W. Mason Macrophage heterogeneity in the rat as delineated by two monoclonal antibodies MRC OX-41 and MRC OX-42, the latter recognizing complement receptor type 3 Immunology 57 1986 239 247 (Pubitemid 16135737)
35. S. Rossi, T. Lo Giudice, V. De Chiara, A. Musella, V. Studer, C. Motta, G. Bernardi, G. Martino, R. Furlan, A. Martorana, and D. Centonze Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis Br. J. Pharmacol. 165 2011 861 869
36. S. Serres, D.C. Anthony, Y. Jiang, K.A. Broom, S.J. Campbell, D.J. Tyler, S.I. van Kasteren, B.G. Davis, and N.R. Sibson Systemic inflammatory response reactivates immune-mediated lesions in rat brain J. Neurosci. 29 2009 4820 4828
37. B. Soliven, V. Miron, and J. Chun The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators Neurology 76 2011 S9 S14
38. B.D. Trapp, J. Peterson, R.M. Ransohoff, R. Rudick, S. Mork, and L. Bo Axonal transection in the lesions of multiple sclerosis N. Engl. J. Med. 338 1998 278 285 (Pubitemid 28065253)
39. L.M. Vaessen, N.M. van Besouw, W.M. Mol, J.N. Ijzermans, and W. Weimar FTY720 treatment of kidney transplant patients: a differential effect on B cells, naive T cells, memory T cells and NK cells Transpl. Immunol. 15 2006 281 288
40. R. Van Doorn, J. Van Horssen, D. Verzijl, M. Witte, E. Ronken, B. Van Het Hof, K. Lakeman, C.D. Dijkstra, P. Van Der Valk, A. Reijerkerk, A.E. Alewijnse, S.L. Peters, and H.E. De Vries Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions Glia 58 2010 1465 1476
41. S.I. van Kasteren, S.J. Campbell, S. Serres, D.C. Anthony, N.R. Sibson, and B.G. Davis Glyconanoparticles allow pre-symptomatic in vivo imaging of brain disease Proc. Natl. Acad. Sci. U. S. A. 106 2009 18 23
42. D. Wheeler, V.V. Bandaru, P.A. Calabresi, A. Nath, and N.J. Haughey A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis Brain 131 2008 3092 3102